(GMCR, STEM, DSCO) CRWENewswire Stocks In Action

StemCells Inc - STEM - reported that the FDA has authorized the initiation of a Phase I/II clinical trial of the Company’s proprietary HuCNS-SC product candidate (purified human neural stem cells) in dry age-related macular degeneration. On its first quarter fiscal 2012, Green Mountain Coffee Roasters Inc - GMCR - posted GAAP operating income of $145.8 million, compared to $23.3 million in the same period the prior year. Discovery Laboratories Inc - DSCO - reported that AFECTAIR is now registered with the FDA and is cleared to be marketed in the United States. AFECTAIR is a proprietary patient interface technology that simplifies delivery of aerosolized medications to patients requiring ventilator support.

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)